Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30706326 | 1.00 | CYP1A2 (0.46) | CYP1A2CYP3A4APOBEC3ACYP2C19APOBEC3G | |
| SCHEMBL30706332 | 0.90 | KDM4E (0.41) | RAB9AMAPTGAAALDH1A1NPC1 | |
| SCHEMBL30706333 | 0.86 | SMN1; SMN2 (0.44) | CYP1A2CYP3A4CYP2C19RAB9ATP53 | |
| SCHEMBL30706334 | 0.86 | SMN1; SMN2 (0.44) | CYP1A2CYP3A4CYP2C19RAB9ATP53 | |
| SCHEMBL30706322 | 0.80 | NR1H2 (0.35) | — | |
| SCHEMBL30706330 | 0.79 | NPC1 (0.44) | RAB9AMAPTGAATRPV1NPC1 | |
| SCHEMBL30706324 | 0.78 | NR1H2 (0.34) | — | |
| SCHEMBL30706327 | 0.76 | LCK (0.38) | RAB9AMAPTGAAPOLB | |
| SCHEMBL30706328 | 0.76 | LCK (0.38) | RAB9AMAPTGAAPOLB | |
| SCHEMBL30706331 | 0.71 | NR1H2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | claimed |
| EP-3885347-B1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORP (JP) | 2023-11-22 | — | — | EP | claimed |
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304913-B2 | Dihydropyrrolopyrazole derivative | CBR3, SLC13A3, CYP3A5 | CYP1A2 34/4885CYP3A4 18/4885APOBEC3A 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.